Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Allergan plc

Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside

Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.

Sales & Earnings Strategy

Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside

Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.

Commercial India

Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August

Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing. 

Financing StartUps and SMEs

Sosei Bolsters GPCR Focus With AbbVie Neurology Deal

The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.

Deals Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Actavis, Inc.
    • Actavis plc
    • Akarna Therapeutics Ltd.
    • Allergan Aesthetics
    • Allergan, Inc.
    • Anterios, Inc.
    • Arrow Group (Subsidiaries: Arrow Generics (U.K), Cobalt Group (U.S.))
    • AqueSys, Inc.
    • Bonti, Inc.
    • Chase Pharmaceuticals Corporation, Inc.
    • Durata Therapeutics
    • Elastagen Pty Ltd
    • EndoArt SA
    • Envy Medical, Inc.
    • Forest Laboratories [Aptalis Pharmaceutical Technologies
    • (Axcan Pharma, Inc.
    • Eurand N.V.
    • Mpex Pharmaceuticals, Inc.)
    • Cerexa, Inc.
    • Clinical Data, Inc.]
    • Furiex Pharmaceuticals, Inc. (PPD, Inc.)
    • Kythera Biopharmaceuticals, Inc.
    • MAP Pharmaceuticals
    • Motus Therapeutics, Inc. (Rhythm Health, Inc.)
    • Naurex, Inc.
    • Oculeve
    • Regado Biosciences, Inc.
    • RetroSense Therapeutics, LLC
    • Silom Medical Company
    • Uteron Pharma SA
    • Warner Chilcott PLC (Galen Holdings PLC)
    • Watson Pharmaceuticals, Inc.
    • Tobira Therapeutics, Inc.
    • Topokine Therapeutics
    • Vitae Pharmaceuticals, Inc.
    • ForSight VISION5, Inc.
    • LifeCell Corporation
    • ZELTIQ Aesthetics, Inc.
    • Zonagen, Inc.
    • Repros Therapeutics, Inc.
UsernamePublicRestriction

Register